RonaldWayneTakvorianMD
Internal Medicine • Boston, MAHematology/Oncology
Assistant Professor of Medicine Harvard Medical School
Dr. Takvorian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yaw 7b Hematology Oncology
Boston, MA 02114Phone+1 617-724-1134Fax+1 617-724-1137
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1977 - 1979
University of Pennsylvania Health SystemResidency, Internal Medicine, 1974 - 1977
Stanford University School of MedicineClass of 1974
Certifications & Licensure
MA State Medical License 1977 - 2025
PA State Medical License 1975 - 1978
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 3 citationsFive-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva
Blood Advances. 2024-02-27 - 6 citationsMetabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.Hazim S Ababneh, Andrea K Ng, Jeremy S Abramson, Jacob D Soumerai, Ronald W Takvorian
Hematological Oncology. 2024-01-01 - 2 citationsIbrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.Reem Karmali, Jeremy S Abramson, Deborah M Stephens, Jeffrey Barnes, Jane N Winter
Blood Advances. 2023-12-12
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
